Aadi Bioscience (NASDAQ:AADI) Stock Price Down 1.2% – Should You Sell?

Shares of Aadi Bioscience, Inc. (NASDAQ:AADI) traded down 1.2% on Monday . The stock traded as low as $1.60 and last traded at $1.60. 140,334 shares changed hands during mid-day trading, a decline of 46% from the average session volume of 261,100 shares. The stock had previously closed at $1.62.

Aadi Bioscience Stock Down 1.2%

The firm has a market capitalization of $39.52 million, a price-to-earnings ratio of -0.70 and a beta of 0.68. The company has a fifty day moving average price of $1.89 and a two-hundred day moving average price of $1.94.

Institutional Investors Weigh In On Aadi Bioscience

Large investors have recently modified their holdings of the company. Two Sigma Advisers LP boosted its holdings in shares of Aadi Bioscience by 95.2% in the fourth quarter. Two Sigma Advisers LP now owns 61,686 shares of the company’s stock valued at $195,000 after acquiring an additional 30,086 shares during the period. Two Sigma Investments LP boosted its holdings in shares of Aadi Bioscience by 305.2% in the fourth quarter. Two Sigma Investments LP now owns 68,555 shares of the company’s stock valued at $216,000 after acquiring an additional 51,638 shares during the period. Northern Trust Corp boosted its holdings in shares of Aadi Bioscience by 33.1% in the fourth quarter. Northern Trust Corp now owns 91,151 shares of the company’s stock valued at $288,000 after acquiring an additional 22,677 shares during the period. Bridgeway Capital Management LLC boosted its holdings in shares of Aadi Bioscience by 23.7% in the fourth quarter. Bridgeway Capital Management LLC now owns 115,400 shares of the company’s stock valued at $364,000 after acquiring an additional 22,100 shares during the period. Finally, Geode Capital Management LLC boosted its holdings in shares of Aadi Bioscience by 4.1% in the fourth quarter. Geode Capital Management LLC now owns 217,294 shares of the company’s stock valued at $686,000 after acquiring an additional 8,546 shares during the period. 52.08% of the stock is owned by institutional investors and hedge funds.

Aadi Bioscience Company Profile

Aadi Bioscience, Inc, a biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug product candidate comprises FYARRO, a form of sirolimus protein-bound particles for injectable suspension for the treatment in adult patients with advanced unresectable or metastatic malignant PEComa.